FY2025 EPS Estimates for CervoMed Cut by Chardan Capital

CervoMed Inc. (NASDAQ:CRVO) – Investment analysts at Chardan Capital dropped their FY2025 earnings estimates for CervoMed in a report released on Tuesday, November 11th. Chardan Capital analyst D. Gataulin now forecasts that the company will post earnings of ($2.94) per share for the year, down from their prior forecast of ($2.56). Chardan Capital currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Chardan Capital also issued estimates for CervoMed’s FY2026 earnings at ($2.07) EPS.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The firm had revenue of $0.32 million for the quarter, compared to analysts’ expectations of $1.43 million. CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%.

Other equities analysts have also issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of CervoMed in a research note on Wednesday, October 8th. Roth Capital set a $20.00 price objective on shares of CervoMed and gave the company a “buy” rating in a research note on Friday, October 17th. HC Wainwright raised shares of CervoMed from a “neutral” rating to a “buy” rating and raised their target price for the stock from $11.00 to $25.00 in a research report on Wednesday, November 5th. Zacks Research downgraded shares of CervoMed from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. Finally, Canaccord Genuity Group increased their price target on shares of CervoMed from $21.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $21.86.

CervoMed Stock Down 2.2%

Shares of CervoMed stock opened at $7.25 on Friday. CervoMed has a fifty-two week low of $1.80 and a fifty-two week high of $16.94. The business’s fifty day moving average is $7.94 and its two-hundred day moving average is $8.17. The firm has a market cap of $67.08 million, a PE ratio of -2.78 and a beta of -0.89.

Institutional Investors Weigh In On CervoMed

Several institutional investors and hedge funds have recently modified their holdings of the stock. Readystate Asset Management LP acquired a new stake in shares of CervoMed in the third quarter valued at about $118,000. GSA Capital Partners LLP purchased a new stake in shares of CervoMed during the third quarter valued at approximately $91,000. Vanguard Group Inc. lifted its holdings in CervoMed by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock worth $2,779,000 after buying an additional 3,445 shares in the last quarter. Savvy Advisors Inc. purchased a new position in CervoMed in the 3rd quarter valued at about $210,000. Finally, Thompson Davis & CO. Inc. grew its stake in shares of CervoMed by 20.8% during the third quarter. Thompson Davis & CO. Inc. now owns 16,850 shares of the company’s stock valued at $136,000 after acquiring an additional 2,900 shares in the last quarter. Hedge funds and other institutional investors own 25.15% of the company’s stock.

Insider Buying and Selling at CervoMed

In other CervoMed news, Director Sylvie Gregoire bought 5,553 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were acquired at an average price of $7.35 per share, with a total value of $40,814.55. Following the purchase, the director owned 1,467,131 shares in the company, valued at approximately $10,783,412.85. The trade was a 0.38% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO John J. Alam purchased 5,553 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were acquired at an average cost of $7.35 per share, with a total value of $40,814.55. Following the completion of the transaction, the chief executive officer owned 1,467,131 shares in the company, valued at $10,783,412.85. This trade represents a 0.38% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 14,606 shares of company stock valued at $107,669 over the last ninety days. Corporate insiders own 35.40% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.